Guardant Health Monroe converts stock awards to shares

Q: How many RSUs did Guardant Health's Chief People Officer convert?

Terilyn J. Monroe reported converting 2,659 and 1,360 restricted stock units into the same respective numbers of common shares on October 1, 2026.

Q: How many Guardant Health shares were withheld for taxes, and at what price?

2,098 shares were retained by the company at $174.75 per share to meet tax withholding obligations connected with vesting. The footnote states the amount retained was not in excess of the tax liability.

The reported activity includes two restricted-stock-unit conversions and company retention of shares for tax withholding.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) Chief People Officer Terilyn J. Monroe reported conversion of 2,659 and 1,360 restricted stock units into the same respective numbers of common shares on October 1, 2026. On that date, 2,098 shares were retained by the company to meet tax withholding obligations tied to vesting, at $174.75 per share. The footnote states the amount retained was not in excess of the tax liability.

Insider Trade Summary

4,019 shares exercised/converted

Exercise 5 txns

Insider Monroe Terilyn J.

Role Chief People Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units ^{F2, F3}	2,659	$0.00	$0.00
Exercise	Restricted Stock Units ^{F4, F3}	1,360	$0.00	$0.00
Exercise	Common Stock	2,659	$0.00	$0.00
Exercise	Common Stock	1,360	$0.00	$0.00
Tax Withholding	Common Stock ^F1	2,098	$174.75	$367K

Holdings After Transaction: Restricted Stock Units — 18,799 contracts (Direct); Common Stock — 24,900 shares (Direct)

Footnotes (4)

F1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2. This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F3. Not applicable for Restricted Stock Units.
F4. This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Key Figures

Restricted stock units converted: 2,659 shares Common shares acquired: 2,659 shares Restricted stock units converted: 1,360 shares +3 more

6 metrics

Restricted stock units converted 2,659 shares October 1, 2026

Common shares acquired 2,659 shares From the restricted stock unit conversion on October 1, 2026

Restricted stock units converted 1,360 shares October 1, 2026

Common shares acquired 1,360 shares From the restricted stock unit conversion on October 1, 2026

Shares retained for tax withholding 2,098 shares October 1, 2026

Per-share price for tax-withheld shares $174.75 per share October 1, 2026

Key Terms

restricted stock unit award, vests in equal quarterly installments, tax withholding obligations

3 terms

restricted stock unit award financial

"This represents a restricted stock unit award granted"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

vests in equal quarterly installments financial

"remaining 67% of the shares vests in equal quarterly installments"

tax withholding obligations financial

"to meet the tax withholding obligations of the award-holder"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RSUs did Guardant Health's Chief People Officer convert?

Terilyn J. Monroe reported converting 2,659 and 1,360 restricted stock units into the same respective numbers of common shares on October 1, 2026.

How many Guardant Health shares were withheld for taxes, and at what price?

2,098 shares were retained by the company at $174.75 per share to meet tax withholding obligations connected with vesting. The footnote states the amount retained was not in excess of the tax liability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/02/2026 - 05:01 PM Accepted by SEC EDGAR 10/02/2026 - 05:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monroe Terilyn J.

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief People Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		M		2,659	A	$0	25,638	D
Common Stock	10/01/2026		M		1,360	A	$0	26,998	D
Common Stock	10/01/2026		F		2,098⁽¹⁾	D	$174.75	24,900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	10/01/2026		M			2,659	⁽²⁾	⁽³⁾	Common Stock	2,659	$0	10,637	D
Restricted Stock Units	$0	10/01/2026		M			1,360	⁽⁴⁾	⁽³⁾	Common Stock	1,360	$0	8,162	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

3. Not applicable for Restricted Stock Units.

4. This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Terilyn J. Monroe	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR